Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses

Giorgio Treglia 1,2,3,*,†, Barbara Muoio 4,†, Gianluca Trevisi 5, Maria Vittoria Mattoli 6, Domenico Albano 7, Francesco Bertagna 7,‡ and Luca Giovanella 1,8,‡

1 Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland; luca.giovanella@eoc.ch
2 Health Technology Assessment Unit, Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland
3 Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland
4 Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland; barbara.muoio@eoc.ch
5 Neurosurgical Unit, Presidio Ospedaliero Santo Spirito, IT-65124 Pescara, Italy; trevisi.gianluca@gmail.com
6 Department of Neurosciences, Imaging and Clinical Sciences, “G. D’Annunzio” University, IT-66100 Chieti, Italy; mvittoriamattoli@yahoo.it
7 Department of Nuclear Medicine, Spedali Civili of Brescia and University of Brescia, IT-25123 Brescia, Italy; doalba87@libero.it (D.A.); francesco.bertagna@unibs.it (F.B.)
8 Department of Nuclear Medicine, University Hospital Zurich and University of Zurich, CH-8091 Zurich, Switzerland

* Correspondence: giorgio.treglia@eoc.ch; Tel.: +41-91-811-1415
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.

Received: 23 August 2019; Accepted: 19 September 2019; Published: 20 September 2019

Abstract: Background: Several meta-analyses reporting data on the diagnostic performance or prognostic value of positron emission tomography (PET) with different tracers in detecting brain tumors have been published so far. This review article was written to summarize the evidence-based data in these settings. Methods: We have performed a comprehensive literature search of meta-analyses published in the Cochrane library and PubMed/Medline databases (from inception through July 2019) about the diagnostic performance or prognostic value of PET with different tracers in patients with brain tumors. Results: We have summarized the results of 24 retrieved meta-analyses on the use of PET or PET/computed tomography (CT) with different tracers in brain tumors. The tracers included were: fluorine-18 fluorodeoxyglucose (18F-FDG), carbon-11 methionine (11C-methionine), fluorine-18 fluoroethyltyrosine (18F-FET), fluorine-18 dihydroxyphenylalanine (18F-FDOPA), fluorine-18 fluorothymidine (18F-FLT), and carbon-11 choline (11C-choline). Evidence-based data demonstrated good diagnostic performance of PET with different tracers in detecting brain tumors, in particular, radiolabelled amino acid tracers showed the highest diagnostic performance values. All the PET tracers evaluated had significant prognostic value in patients with glioma. Conclusions: Evidence-based data showed a good diagnostic performance for some PET tracers in specific indications and significant prognostic value in brain tumors.

Keywords: PET; positron emission tomography; brain tumors; glioma; brain metastases; diagnostic performance; prognosis; meta-analysis
1. Introduction

Positron emission tomography (PET) is a nuclear medicine imaging technique that, using different radiotracers evaluating different metabolic patterns, is able to detect in advance pathophysiological changes in oncological patients, including those with brain tumors. These functional changes usually occur before the development of morphological changes detected by conventional radiological imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) [1]. MRI is the standard neuroimaging method used for diagnosis of brain tumors, for performing stereotactic biopsy, and for surgical planning in neuro-oncology [2]. Currently, hybrid imaging techniques such as PET/CT and PET/MRI, providing a combination of both functional and morphological information, may be useful methods for early diagnosis of brain tumors [1,2].

Different PET radiotracers have been used to evaluate brain tumors, including fluorine-18 fluorodeoxyglucose (\(^{18}\text{F}-\text{FDG}\)), carbon-11 methionine (\(^{11}\text{C}-\text{methionine}\)), fluorine-18 fluoroethyltyrosine (\(^{18}\text{F}-\text{FET}\)), fluorine-18 fluorodihydroxyphenylalanine (\(^{18}\text{F}-\text{FDOPA}\)), fluorine-18 fluorothymidine (\(^{18}\text{F}-\text{FLT}\)), and radiolabelled choline (\(^{11}\text{C}-\text{choline}\) or \(^{18}\text{F}-\text{choline}\)).

\(^{18}\text{F}-\text{FDG}\) is the most used PET radiotracer in oncology; it is a radiolabelled glucose analogue taken up by neoplastic cells via cell membrane glucose transporters (GLUT) and subsequently phosphorylated through the activity of intracellular hexokinase. \(^{18}\text{F}-\text{FDG}\) allows the detection of neoplastic cells due to their frequently increased glucose metabolism [1]. The main concerns about the use of \(^{18}\text{F}-\text{FDG}\) PET for evaluating brain lesions are the high background \(^{18}\text{F}-\text{FDG}\) uptake in the normal brain [1] and the increased \(^{18}\text{F}-\text{FDG}\) uptake in inflammatory or benign lesions [3]. Therefore, other PET tracers characterized by increased uptake in brain tumors and low uptake in the normal brain have been developed in recent decades [1].

\(^{11}\text{C}-\text{methionine}\) is a radiolabelled amino acid; methionine is used by the cells in two main metabolic functions: protein synthesis and conversion to S-adenosylmethionine. In many neoplastic cells, there is an increase in protein synthesis, transmethylation and transsulfuration, leading to an increased uptake of \(^{11}\text{C}-\text{methionine}\) [1,4]. Unfortunately, the use of this PET tracer is restricted to PET centers with a cyclotron facility because of the shorter half-life of \(^{11}\text{C}\) compared to \(^{18}\text{F}\) (20 min versus 110 min, respectively) [4].

\(^{18}\text{F}-\text{FET}\) is a fluorinated amino acid used to detect brain tumors. \(^{18}\text{F}-\text{FET}\) is taken up into neoplastic cells due to their increased amino acid uptake through an L-type amino acid transport system, and it is not incorporated into proteins [2].

\(^{18}\text{F}-\text{FDOPA}\) has been proposed as a useful PET tracer for imaging brain tumors. \(^{18}\text{F}-\text{FDOPA}\) is transported across the blood-brain barrier by a number of amino acid transporters, which have been shown to be overexpressed in brain tumors. After intracellular uptake through the large amino acid transporter, \(^{18}\text{F}-\text{FDOPA}\) is decarboxylated by DOPA decarboxylase to \(^{18}\text{F}-\text{dopamine}\), which is transported into storage granules by vesicular monoamine transporters and trapped intracellularly [1,5].

\(^{18}\text{F}-\text{FLT}\) is a tracer proposed as an imaging biomarker of cell proliferation, which is increased in neoplastic cells; during the S phase of the cell cycle, \(^{18}\text{F}-\text{FLT}\) is phosphorylated by thymidine-kinase-1 and trapped inside the cell but not incorporated into the DNA. The cellular thymidine-kinase-1 activity has been reported to be proportional to the proliferation activity of the tumor [6].

Lastly, as tumor cells present a high turnover of cellular membranes, radiolabelled choline (using \(^{11}\text{C}\) or \(^{18}\text{F}\)) may be used to detect brain tumors. The uptake of radiolabelled choline increases in tumor tissue to keep up with the demands of phospholipids synthesis in cellular membranes [1,7].

Enough literature data already exist about the diagnostic performance and prognostic value of PET with different tracers in brain tumors. Therefore, we aimed to summarize the findings of published meta-analyses in these settings.

2. Methods

A comprehensive computer literature search of the Cochrane library and PubMed/Medline databases was performed to find published meta-analyses on the diagnostic performance or prognostic
value of PET or hybrid PET/CT or PET/MRI in patients with brain tumors. The search algorithm is reported in the Appendix A. The literature search was updated until July 31st, 2019. No language restriction was used. Meta-analyses investigating the diagnostic performance or prognostic value of PET or PET/CT or PET/MRI with different tracers in brain tumors were eligible for inclusion. We reviewed titles and abstracts of the retrieved articles, applying the selected inclusion criteria. For each selected meta-analysis, we collected information about basic study characteristics (authors, year of publication, number of original studies included, number of patients included, clinical indications, and radiotracer used) and pooled diagnostic performance measures (sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratios) including 95% confidence interval values (95% CI). Moreover, we have briefly described the main findings of the selected diagnostic or prognostic meta-analyses in the results section.

3. Results

Twenty-four meta-analyses on the use of PET or PET/CT with different tracers in brain tumors, published from 2012, were selected through the comprehensive computer literature search (Figure 1) [8–31]. The characteristics of the selected meta-analyses on the diagnostic performance are presented in Table 1. Here, below, we have summarized the main findings of the meta-analytic studies based on the different clinical indications of PET or PET/CT.

![Flow chart](image)

**Figure 1.** Flow chart of the search for meta-analyses on the diagnostic performance and prognostic value of positron emission tomography (PET) with different tracers in patients with brain tumors.
Table 1. Characteristics and main findings of included meta-analyses on the diagnostic performance of PET or PET/computed tomography (CT) with different tracers in patients with brain tumors.

| Indication                        | Tracer         | Authors            | Year | Articles Included | Patients Included | Sensitivity (95% CI) | Specificity (95% CI) | LR + (95% CI) | LR – (95% CI) | DOR (95% CI) |
|----------------------------------|----------------|--------------------|------|-------------------|-------------------|----------------------|----------------------|---------------|---------------|--------------|
| **Evaluation of Suspicious Primary Brain Tumor** | 18F-FDG        | Zhao et al. [28]   | 2014 | 3                 | 127               | 43% (29–59)          | 74% (49–90)          | 1.7 (0.6–4.8) | 0.77 (0.48–1.24) | NR           |
|                                  |                | Dunet et al. [25]  | 2016 | 5                 | 119               | 38% (27–50)          | 86% (31–99)          | 2.7 (0.3–27.8) | 0.72 (0.47–1.11) | 4 (0–58)     |
|                                  | 11C-methionine | Zhao et al. [28]   | 2014 | 2                 | 85                | 95% (85–98)          | 83% (65–93)          | 5.5 (2.5–12.2) | 0.07 (0.02–0.2) | 4 (0–58)     |
|                                  | 18F-FET        | Dunet et al. [31]  | 2012 | 5                 | 224               | 82% (74–88)          | 76% (44–92)          | 3.4 (1.2–9.5) | 0.24 (0.14–0.39) | 14 (3–60)    |
|                                  |                | Dunet et al. [25]  | 2016 | 5                 | 119               | 94% (79–98)          | 88% (37–99)          | 8.1 (0.8–80.6) | 0.07 (0.02–0.30) | 113 (4–2975) |
|                                  | 18F-FDOPA      | Xiao et al. [8]    | 2019 | 5                 | 46                | 71% (54–85)          | 86% (42–100)         | 3.7 (0.9–15.8) | 0.36 (0.19–0.68) | 10.88 (1.57–75.31) |
| **Glioma Grading**               | 18F-FDG        | Dunet et al. [25]  | 2016 | 2                 | 63                | 60% (mean TBR ≥1.4) | 91% (mean TBR ≥1.4) | NR           | NR           |
|                                  |                | Katsanos et al. [11] | 2019 | 13                | 680               | 63% (51–74)          | 89% (73–95)          | 5.2 (2.1–13) | 0.42 (0.29–0.6) | 12.4 (3.86–39.8) |
|                                  | 11C-methionine | Falk Delgado et al. [19] | 2018 | 13                | 241               | 80% (66–88)          | 72% (62–81)          | NR           | NR           |
|                                  |                | Katsanos et al. [11] | 2019 | 8                 | 191               | 94% (79–98)          | 55% (32–77)          | 2.1 (1.25–3.5) | 0.11 (0.03–0.37) | 18.25 (4.73–70.5) |
| **Glioma Delineation**           | 18F-FET        | Dunet et al. [25]  | 2016 | 2                 | 63                | 88% (mean TBR ≥2)   | 73% (mean TBR ≥2)   | NR           | NR           |
|                                  |                | Katsanos et al. [11] | 2019 | 7                 | 259               | 88% (82–93)          | 57% (40–73)          | 2.1 (1.4–3.15) | 0.2 (0.11–0.37) | 10.16 (3.9–26.5) |
|                                  | 18F-FDOPA      | Xiao et al. [8]    | 2019 | 7                 | 219               | 88% (81–93)          | 73% (64–81)          | 2.9 (2.2–3.85) | 0.16 (0.08–0.436) | 25.87 (10.53–63.54) |
| **Diagnosis of Recurrent Brain Tumor** | 11C-methionine | Verburg et al. [21] | 2017 | 5                 | NR                | [HGG] 93.7%          | [HGG] 61.3%          | NR           | NR           |
|                                  | 18F-FDG        | Nihashi et al. [30] | 2013 | 16                | NR                | 77% (66–85)          | 78% (54–91)          | 3.4 (1.6–7.5) | 0.3 (0.21–0.43) | NR           |
|                                  |                | Zhao et al. [28]   | 2014 | 20                | 643               | 75% (67–81)          | 79% (66–88)          | 3.5 (2.2–5.7) | 0.32 (0.25–0.41) | NR           |
| Indication                      | Tracer | Authors            | Year | Articles Included | Patients Included | Sensitivity (95% CI) | Specificity (95% CI) | LR + (95% CI) | LR – (95% CI) | DOR (95% CI) |
|--------------------------------|--------|--------------------|------|-------------------|-------------------|----------------------|----------------------|---------------|---------------|--------------|
| Diagnosis of Recurrent Brain Tumor | 18F-FDG | Li et al. [26]     | 2015 | 22                | NR                | 78% (69–85)          | 77% (66–85)          | 3.3 (2.2–5)  | 0.29 (0.20–0.42) | 12 (6–22)    |
|                                |        | Wang et al. [27]   | 2015 | 12               | 418               | 70% (64–75)          | 88% (80–93)          | 4 (2.1–7.5)  | 0.38 (0.29–0.51) | NR           |
|                                |        | Furuse et al. [12] | 2019 | 9                | 327               | 81% (67–90)          | 72% (64–79)          | NR            | NR            | NR           |
|                                |        | Nihashi et al. [30]| 2013 | 7                | NR                | [HGG] 70% (50–84)    | [HGG] 93% (44–100)   | 4.35 (2.8–6.8) | 0.19 (0.13–0.29) | NR           |
|                                |        | Deng et al. [29]   | 2013 | 11               | 244               | 87% (81–91.8)        | 81.3% (71.5–88.8)    | 6.8 (3.4–13.7) | 0.09 (0.04–0.21) | NR           |
|                                |        | Zhao et al. [28]   | 2014 | 8                | 238               | 92% (83–97)          | 87% (75–93)          | 6.8 (3.4–13.7) | 0.09 (0.04–0.21) | NR           |
|                                |        | Wang et al. [27]   | 2015 | 6                | 156               | 85% (76–91)          | 83% (71–92)          | 4.4 (2.5–7.7) | 0.22 (0.13–0.35) | NR           |
|                                |        | Xu et al. [18]     | 2017 | 29               | 899               | 88% (85–91)          | 85% (80–89)          | 5.3 (3.3–8.7) | 0.16 (0.11–0.23) | 35.3 (22.9–54.4) |
|                                |        | Furuse et al. [12] | 2019 | 8                | 333               | 81% (73–87)          | 81% (74–87)          | NR            | NR            | NR           |
|                                |        | Yu et al. [16]     | 2018 | 27               | NR                | 82% (79–84)          | 80% (76–83)          | 3.9 (3.0–5.1) | 0.17 (0.10–0.27) | 23.03 (14.42–36.77) |
|                                |        | Furuse et al. [12] | 2019 | 3                | 138               | 91% (79–97)          | 95% (61–99)          | NR            | NR            | NR           |
|                                |        | Yu et al. [16]     | 2018 | 21               | NR                | 85% (81–88)          | 77% (74–81)          | 3.4 (2.8–4.3) | 0.21 (0.16–0.29) | 21.7 (12.61–37.33) |
|                                |        | Xiao et al. [8]    | 2019 | 13               | 318               | 92% (88–95)          | 76% (66–85)          | 2.9 (2–4.1)   | 0.13 (0.07–0.23) | 29.65 (13–69–67–15) |
|                                |        | Kim et al. [9]     | 2019 | 6                | 212               | 89% (82–94)          | 88% (76–94)          | 7.3 (5.6–14.7) | 0.12 (0.07–0.21) | 60 (23–152)   |
|                                |        | Li et al. [26]     | 2015 | 5                | NR                | 82% (51–95)          | 76% (50–91)          | 3.5 (1.6–7.7) | 0.24 (0.08–0.70) | 15 (4–56)    |
|                                |        | Gao et al. [14]    | 2018 | 6                | 118               | 87% (78–93)          | 82% (69–91)          | 4.9 (2.6–9.1) | 0.16 (0.09–0.29) | 35.5 (11.7–107.7) |
### Table 1. Cont.

| Indication                  | Tracer | Authors            | Year | Articles Included | Patients Included | Sensitivity (95% CI) | Specificity (95% CI) | LR + (95% CI) | LR − (95% CI) | DOR (95% CI) |
|-----------------------------|--------|--------------------|------|-------------------|-------------------|----------------------|---------------------|--------------|--------------|-------------|
| Diagnosis of Brain Metastases | ¹⁸F-FDG | Li et al. [24]     | 2017 | 5                 | 941               | 21% (13–32)         | 100% (99–100)       | 184.7 (24.8–1374) | 0.79 (0.70–0.89) | 235 (31–1799) |
|                             |        | Li et al. [17]     | 2018 | 6                 | NR                | 85% (77–94)         | 90% (83–96)         | NR           | NR           | NR          |
|                             |        | Suh et al. [13]    | 2018 | 5                 | NR                | 83% (74–92)         | 88% (81–95)         | NR           | NR           | NR          |
|                             |        | Furuse et al. [12] | 2019 | 3                 | NR                | 91% (73–97)         | 80% (60–91)         | NR           | NR           | NR          |
| Diagnosis of Recurrent Brain Metastases | ¹⁸F-FDG | Li et al. [17]     | 2018 | 2                 | NR                | 86% (74–97)         | 79% (66–93)         | NR           | NR           | NR          |
|                             |        | Furuse et al. [12] | 2019 | 4                 | NR                | 79% (67–87)         | 76% (61–87)         | NR           | NR           | NR          |
| Diagnosis of PCNSL          | ¹⁸F-FET | Li et al. [17]     | 2018 | 5                 | NR                | 83% (76–91)         | 89% (83–95)         | NR           | NR           | NR          |
|                             |        | Yu et al. [16]     | 2018 | 4                 | NR                | 80% (76–84)         | 79% (75–83)         | 3.9          | 0.24         | 19          |
| Diagnosis of PCNSL          | ¹⁸F-FDOPA | Li et al. [17]    | 2018 | 2                 | NR                | 86% (74–97)         | 88% (79–97)         | NR           | NR           | NR          |
|                             |        | Yu et al. [16]     | 2018 | 2                 | NR                | 78% (73–82)         | 75% (71–89)         | 3            | 0.31         | 11          |
| Diagnosis of PCNSL          | AA *   | Suh et al. [13]    | 2018 | 7                 | NR                | 84% (79–90)         | 85% (80–91)         | NR           | NR           | NR          |
| Diagnosis of PCNSL          | ¹⁸F-FDG | Zhou et al. [22]   | 2017 | 8                 | 129               | 88% (80–94)         | 86% (73–94)         | 4            | 0.11 (0.04–0.32) | 33.4 (10.4–107.3) |
|                             |        | Yang et al. [23]   | 2017 | 6                 | 108               | NR                  | NR                  | NR           | NR           | NR          |

Legend: LR+ = positive likelihood ratio; LR− = negative likelihood ratio; DOR = diagnostic odds ratio; 95% CI = 95% confidence interval; AA * = radiolabelled amino acid PET including radiolabelled methionine, fluoroethyltyrosine and fluorodihydroxyphenylalanine; NR = not reported; HGG = high grade gliomas only; PCNSL = primary central nervous system lymphoma; mean TBR = mean tumor-to-background uptake ratio; max TBR = maximum tumor-to-background uptake ratio.
3.1. Evaluation of Suspicious Primary Brain Tumor

Four meta-analyses have assessed the diagnostic performance of PET or PET/CT with different tracers in patients for whom primary brain tumors are suspected [8,25,28,31]. Pooled results are showed in Figure 2.

![Figure 2](link)

**Figure 2.** Graph showing 95% confidence intervals of sensitivity (continuous line) and specificity (dashed line) of PET with different tracers in evaluating suspicious brain tumors, according to published meta-analyses.

### 3.1.1. 18F-FDG

A meta-analysis including patients with suspicious primary brain tumors showed that 18F-FDG PET or PET/CT has a moderate sensitivity and specificity for differentiating brain tumors from non-tumor lesions. False-positive findings were often due to inflammatory lesions or other non-tumor tissues; on the other hand, reduced 18F-FDG uptake in brain tumors is usually influenced by the high physiological glucose metabolism in the surrounding normal brain tissue, leading to a decreased sensitivity [28]. Another meta-analysis also demonstrated that 18F-FDG PET or PET/CT have a moderate diagnostic performance in distinguishing between tumoral and non-tumoral lesions in the brain, lower than amino acid PET [25].

### 3.1.2. 11C-Methionine

A meta-analysis by Zhao et al. demonstrated a good diagnostic performance of 11C-methionine PET or PET/CT in detecting brain tumors (pooled sensitivity and specificity were of 95% and 83%, respectively) with higher diagnostic accuracy values compared to 18F-FDG PET or PET/CT, likely due to the higher 11C-methionine uptake in brain tumors and lower accumulation in normal brain tissue [28].

### 3.1.3. 18F-FET

For initial assessment of patients with a newly diagnosed brain lesion, 18F-FET PET or PET/CT demonstrated a good performance in the diagnosis of a brain tumor with a pooled sensitivity and specificity of 82% and 76%, respectively. A mean tumor-to-background uptake ratio (TBR) threshold of at least 1.6 and a maximum TBR of at least 2.1 had the best diagnostic value for differentiating brain tumors from non-tumoral brain lesions. For the diagnosis of glioma versus non-glioma brain lesions, 18F-FET PET or PET/CT demonstrated a good sensitivity (84%) but an inadequate specificity (62%) [31]. In a head-to-head comparative meta-analysis, the diagnostic performance of 18F-FET PET or PET/CT...
in distinguishing between tumoral and non-tumoral lesions in the brain was found to be significantly higher compared to that of \(^{18}\)F-FDG PET or PET/CT performed in the same patients [25].

3.1.4. \(^{18}\)F-FDOPA

\(^{18}\)F-FDOPA PET or PET/CT revealed a moderate pooled sensitivity (71%) and a good pooled specificity (86%) in detecting newly-diagnosed gliomas [8].

3.2. Glioma Grading

Gliomas are the most frequently occurring primary brain tumors. High grade gliomas like glioblastomas are the most common gliomas in adults, with a poor prognosis with any current therapy. Conversely, low-grade gliomas, the second most common type of gliomas, are potentially curable with appropriate treatment. Several meta-analyses have evaluated the role of PET or PET/CT with different tracers in differentiating between high-grade and low-grade gliomas [8,11,19,25]. Pooled results are showed in Figure 3.

![Figure 3. Graph showing 95% confidence intervals of sensitivity (continuous line) and specificity (dashed line) of PET with different tracers for glioma grading, according to published meta-analyses.](image)

3.2.1. \(^{18}\)F-FDG

\(^{18}\)F-FDG uptake is significantly higher in high-grade gliomas compared to low-grade gliomas. According to the meta-analysis of Dunet et al., a mean TBR of at least 1.4 and a maximum TBR of at least 1.8 at \(^{18}\)F-FDG PET had the best value to distinguish between low- and high-grade gliomas, with a sensitivity, specificity and accuracy of 60%, 91%, and 74%, respectively, for mean TBR and 72%, 73%, and 72%, respectively, for maximum TBR [25]. A recent meta-analysis demonstrated a lower sensitivity of \(^{18}\)F-FDG PET or PET/CT in differentiating between high-grade and low-grade gliomas compared to radiolabelled amino acid PET (\(^{11}\)C-methionine and \(^{18}\)F-FET) but with higher specificity [11].

3.2.2. \(^{11}\)C-Methionine

\(^{11}\)C-methionine PET or PET/CT had a moderate diagnostic accuracy in differentiating between high-grade and low-grade gliomas, according to data provided by a recent meta-analysis (pooled sensitivity and specificity of 80% and 72%, respectively) [19]. Another meta-analysis demonstrated that \(^{11}\)C-methionine PET or PET/CT has a higher sensitivity compared to \(^{18}\)F-FDG PET or PET/CT
in differentiating between high-grade and low-grade gliomas but with lower specificity; diagnostic performance values were similar to those of $^{18}$F-FET PET or PET/CT in this setting [11].

3.2.3. $^{18}$F-FET

$^{18}$F-FET uptake is significantly higher in high-grade gliomas compared with low-grade gliomas. Dunet et al. reported that a mean TBR of at least 2.0 and a maximum TBR of at least 3.0 at $^{18}$F-FET PET reached a sensitivity, specificity, and accuracy of 88%, 73%, and 81%, respectively, for mean TBR, and 80%, 82%, and 81%, respectively, for maximum TBR [25]. A recent meta-analysis demonstrated that $^{18}$F-FET PET or PET/CT has a higher sensitivity compared to $^{18}$F-FDG PET or PET/CT in differentiating between high-grade and low-grade gliomas but with lower specificity; diagnostic performance values were similar to those of $^{11}$C-methionine PET or PET/CT in this setting [11].

3.2.4. $^{18}$F-FDOPA

For differentiating high-grade from low-grade gliomas, $^{18}$F-FDOPA PET or PET/CT showed a pooled sensitivity of 88% and a pooled specificity of 73% [8].

3.3. Delineation of Gliomas

For surgical and radiation therapy planning in patients with glioma, a correct delineation of the target volume is needed. A recent evidence-based article suggested that radiolabelled amino acid PET may ameliorate the delineation of high-grade gliomas compared to standard MRI [21].

3.4. Diagnosis of Recurrent Brain Tumors

Distinguishing recurrent brain tumors from non-tumoral lesions after radiation therapy and/or chemotherapy is a crucial clinical issue, because the different diagnosis will lead to divergent treatments. Several meta-analyses have assessed the diagnostic performance of PET with different tracers in this setting [8,9,12,14,16,18,26–30]. Pooled results are showed in Figure 4.

![Graph showing 95% confidence intervals of sensitivity (continuous line) and specificity (dashed line) of PET with different tracers for diagnosis of recurrent brain tumor, according to published meta-analyses.](image-url)
3.4.1. 18F-FDG

A meta-analysis by Zhao et al. demonstrated a moderate diagnostic accuracy of 18F-FDG PET or PET/CT in detecting brain tumor recurrence [28]. This finding was confirmed by another meta-analysis, which showed a pooled sensitivity and specificity of 78% and 77%, respectively [26]. Furuse et al. showed that the diagnostic performance of 18F-FDG PET or PET/CT in detecting recurrent brain tumors was lower compared to that of radiolabelled amino acid PET or PET/CT [12]. Nihashi et al. showed that, when considering both low- and high-grade gliomas, pooled sensitivity and specificity of 18F-FDG PET or PET/CT in detecting glioma recurrence were 77% and 78%, respectively. In subgroup analyses limited to high-grade gliomas, pooled sensitivity and specificity were 79% and 70%, respectively [30]. Wang et al. reported a moderate sensitivity (70%) but a good specificity (88%) of 18F-FDG PET or PET/CT in detecting recurrent glioma; however, the diagnostic accuracy was lower compared to that of 11C-methionine PET or PET/CT and magnetic resonance spectroscopy in this setting [27]. Another meta-analysis demonstrated that the diagnostic performance of 18F-FDG PET or PET/CT in detecting recurrent glioma is not optimal, in particular if compared with other available neuroimaging methods [12].

3.4.2. 11C-Methionine

11C-methionine PET or PET/CT demonstrated good diagnostic performance in detecting brain tumor recurrence (pooled sensitivity and specificity of 92% and 87%, respectively), with higher values compared to 18F-FDG PET or PET/CT [28]. For high-grade gliomas, pooled sensitivity and specificity of 11C-methionine PET or PET/CT in detecting glioma recurrence were 70% and 93%, respectively [30]. Compared to dynamic susceptibility contrast-enhanced MRI, 11C-methionine PET or PET/CT demonstrated comparable pooled sensitivity and specificity in detecting glioma recurrence, with pooled values of 87% and 81.3%, respectively [29]. Similar values of sensitivity and specificity (85% and 83%, respectively) were described by Wang et al. who demonstrated that the diagnostic performance of 11C-methionine PET or PET/CT in detecting glioma recurrence was similar to that of magnetic resonance spectroscopy [27]. A large meta-analysis including 29 studies confirmed the good diagnostic performance of 11C-methionine PET or PET/CT in this setting, with a pooled sensitivity and specificity of 88% and 85%, respectively [18].

3.4.3. 18F-FET

A recent meta-analysis demonstrated that 18F-FET PET or PET/CT has a good diagnostic accuracy in differentiating between brain tumor recurrence from radiation necrosis after treatment, with pooled sensitivity and specificity values of 82% and 80%, respectively. In the subgroup of patients with suspicious glioma recurrence, sensitivity and specificity of 18F-FET PET or PET/CT were 83% and 81%, respectively [16]. The good diagnostic performance of 18F-FET PET or PET/CT in this setting was also confirmed by Furuse et al., who reported increased diagnostic performance of 18F-FET PET or PET/CT compared to 18F-FDG and 11C-methionine PET or PET/CT [12]. Kim et al. found that amino acid PET or PET/CT, including 18F-FET PET, has a good diagnostic performance in differentiating residual or recurrent brain tumors from treatment-related changes (pseudoprogression) in patients with high-grade gliomas [9].

3.4.4. 18F-FDOPA

A recent meta-analysis indicated that 18F-FDOPA PET or PET/CT has a good diagnostic accuracy in differentiating between brain tumor recurrence from radiation necrosis after treatment, with pooled sensitivity and specificity values of 85% and 77%, respectively. In the subgroup of patients with suspicious glioma recurrence, sensitivity and specificity of 18F-FDOPA PET or PET/CT were 94% and 89%, respectively [16]. Xiao et al. reported a good sensitivity of 18F-FDOPA PET and PET/CT in detecting recurrent glioma (92%) and a moderate specificity (76%) [8].
3.4.5. 18F-FLT

18F-FLT PET or PET/CT demonstrated a similar diagnostic performance in detecting brain tumor recurrence compared to 18F-FDG PET or PET/CT, with pooled sensitivity and specificity of 82% and 76%, respectively [26].

3.4.6. 18C-Choline

A recent meta-analysis indicated that 11C-choline PET or PET/CT has a good diagnostic accuracy for differentiating glioma recurrence from radiation induced necrosis after treatment, with a pooled sensitivity and specificity of 87% and 82%, respectively [14].

3.5. Diagnosis of Brain Metastases

The reliability of PET or PET/CT with different tracers in detecting brain metastases has been evaluated to a less extent compared to primary brain tumors. A meta-analysis demonstrated that the pooled sensitivity and specificity of 18F-FDG PET or PET/CT in detecting brain metastases in patients with lung cancer were 21% and 100%, respectively. In particular, the sensitivity of this method is lower compared to that of contrast-enhanced MRI [24].

3.6. Diagnosis of Recurrent Brain Metastases

The meta-analysis by Li et al., which focused on the use of PET or PET/CT with different tracers in differentiating recurrent brain metastasis from radionecrosis after radiation therapy, demonstrated a good diagnostic accuracy of PET or PET/CT with both 18F-FDG and radiolabelled amino acid tracers (11C-methionine, 18F-FET, 18F-FDOPA) in this setting [17]. MRI and PET with different tracers showed similar diagnostic performance for the detection of recurrent brain metastasis after stereotactic radiosurgery; nevertheless, advanced MRI methods showed a significantly higher diagnostic performance in this setting compared to PET [13]. Pooled results are shown in Figure 5.

3.7. Diagnosis of Primary Central Nervous System Lymphoma (PCNSL)

18F-FDG PET and PET/CT showed considerable accuracy in identifying PCNSL among various brain lesions in immunocompetent patients (pooled sensitivity and specificity of 88% and 86%, respectively [22]. High diagnostic accuracy of 18F-FDG PET and PET/CT has also been demonstrated in identifying PCNSL among various brain lesions in patients with human immunodeficiency virus (HIV) infection [23].

3.8. Prognostic Value In Patients With Glioma

Figure 5. Graph showing 95% confidence intervals of sensitivity (continuous line) and specificity (dashed line) of PET with different tracers for diagnosis of recurrent brain metastasis, according to published meta-analyses.
respectively), therefore, \(^{18}\)F-FDG PET/CT could be a valuable diagnostic imaging method in this setting [22]. High diagnostic accuracy of \(^{18}\)F-FDG PET and PET/CT has also been demonstrated in identifying PCNSL among various brain lesions in patients with human immunodeficiency virus (HIV) infection [23].

### 3.8. Prognostic Value In Patients With Glioma

Beyond the diagnostic accuracy, PET/CT parameters, and particularly the TBR, may be significant prognostic factors in patients with glioma. A recent meta-analysis demonstrated that increased TBR at \(^{18}\)F-FDG PET, \(^{11}\)C-methionine PET and \(^{18}\)F-FET PET could indicate poor overall survival (pooled hazard ratios were 3.05 for \(^{18}\)F-FDG PET, 1.59 for \(^{11}\)C-methionine PET, and 1.15 for \(^{18}\)F-FET PET) [10]. Another meta-analysis showed that the TBR and metabolic tumor volume at \(^{11}\)C-methionine PET are significant prognostic parameters for patients with gliomas. Patients with a high TBR have a higher risk of death, and patients with a high metabolic tumor volume have a higher risk of adverse events or death [15].

### 4. Discussion

Overall, there are increased evidence-based data about the usefulness of PET or PET/CT with different tracers in patients with brain tumors. MRI provides accurate morphological information on brain lesions, whereas PET/CT, using tracers evaluating different metabolic pathways, provides useful information that may definitively improve the diagnostic accuracy of brain tumors if combined with MRI [20,32]. In particular, current evidence based data suggest that radiolabelled amino acid PET or PET/CT is an accurate diagnostic method for several clinical indications including evaluation of suspicious brain tumors, glioma grading and delineation, and detection of brain tumor recurrence. Furthermore, PET/CT with \(^{18}\)F-FDG or radiolabelled amino acids may provide useful prognostic information in patients with brain tumors.

In addition to the different characteristics of the various PET tracers, different imaging modalities, such as PET alone compared to PET/CT or PET/MRI, will affect the sensitivity and specificity. In fact, higher diagnostic accuracy values can be obtained by using hybrid modalities compared to PET alone. Overall, the studies in the literature, in various degree, suggested that PET/CT with different tracers may show brain tumor boundaries better than conventional MRI. But compared to PET/CT, conventional MRI can more clearly show the anatomical structure, which is a function that cannot be replaced by PET/CT with any tracer. Therefore, PET/CT and MRI are often combined to evaluate brain tumors in order to achieve a higher accuracy compared to single imaging methods [20].

Awareness of the results described by several published meta-analyses on this topic has the potential to affect patient care by providing supportive evidence-based data for a more effective use of PET/CT with different tracers in the diagnosis of brain tumors. In this regard, recent published international guidelines support nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of PET/CT with different tracers in patients with glioma [32]. PET/CT with different tracers may be useful to direct therapeutic strategies improving patient outcome in patients with brain tumors; nevertheless, prospective outcome studies are needed because the diagnostic accuracy of PET or PET/CT with different tracers is not a measure of clinical effectiveness, and a good diagnostic performance does not necessarily result in improved outcomes in patients with brain tumors. Furthermore, several factors beyond the diagnostic performance may influence the choice of a specific PET tracer for evaluating brain tumors, such as tracer availability, radiation dose, and the presence of a cyclotron facility, as well as safety, legal, organizational, and economic aspects.

Several limitations of the selected meta-analyses should be discussed because they could hamper the ability to obtain definitive conclusions on the diagnostic performance or prognostic value of PET or PET/CT with different tracers in patients with brain tumors. In several selected meta-analyses, a limited number of original articles was included, and many of them had a small sample size. The limited number of cumulative patients available for the quantitative analysis may reduce the statistical power
of the meta-analysis [33,34]. Furthermore, in some meta-analyses, a significant statistical heterogeneity among included studies was found, leading to a significant bias. This heterogeneity is likely due to differences in patient characteristics, methodological aspects (including different PET interpretation criteria), and study quality among the different included studies [33,34]. Some studies included in the meta-analyses used an imperfect reference standard (other than histology), which may have produced biased results. Moreover, publication bias (due to the higher probability of publishing studies reporting significant findings than those reporting non-significant results) has been detected in some meta-analyses.

Some indications of PET or PET/CT with different tracers in patients with brain tumors were not evaluated by published meta-analyses. In particular, there are no published meta-analyses about PET imaging with different tracers in evaluating other tumors of the central nervous system such as acoustic neuromas, chordomas, craniopharyngiomas, ependymomas, optic nerve gliomas, medulloblastomas, meningiomas, pituitary adenomas, etc.

To date, there is an increased use of PET/CT with radiolabelled somatostatin analogues in patients with meningiomas due to the overexpression of somatostatin receptors by these tumors. Compared with standard MRI, somatostatin receptor PET may add valuable additional diagnostic information in these patients, particularly in the differential diagnosis of newly diagnosed brain lesions suspicious for meningiomas, delineation of meningioma extent for resection or radiotherapy planning, and the differentiation of tumor progression from a post-treatment change [35].

Furthermore, there are no meta-analyses about the diagnostic performance of PET with other emerging tracers for evaluation of brain tumors, such as radiolabelled prostate-specific membrane antigen (PSMA) [36] or fluorine-18 fluciclovine (18F-FACBC) [37], or with extensively studied tracers such as α-[11C]methyl-L-tryptophan [38].

Hybrid PET/MRI tomographs are now available for clinical use, and the role of PET/MRI using different PET tracers in brain tumors is promising, but more evidence-based data are needed in this setting [20].

Large multicenter prospective studies and, in particular, more cost-effectiveness analyses comparing different PET tracers and different neuroimaging modalities in patients with brain tumors are warranted. To this end, some cost-effectiveness analyses on the use of amino acid PET or PET/CT in brain tumors are already available, demonstrating that the combination of amino acid PET and MRI may be cost-effective for target selection in patients with suspicious glioma, for the surgical plan in patients with high-grade glioma, and for the evaluation of patients with suspicious recurrent high-grade glioma or brain metastasis [39–42].

Author Contributions: Conceptualization, G.T. (Giorgio Treglia) and B.M.; methodology, G.T. (Giorgio Treglia); validation, G.T. (Gianluca Trevisi), M.V.M., D.A., and F.B.; resources, B.M.; data curation, G.T. (Giorgio Treglia); writing—original draft preparation, G.T. (Giorgio Treglia) and B.M.; writing—review and editing, G.T. (Gianluca Trevisi), M.V.M., D.A., and F.B.; supervision, L.G.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

String used for database search: ((PET) OR (positron emission tomography)) AND ((glioma *) OR (PCNSL) OR (((brain) OR (cerebral)) AND ((lesion *) OR (tumors) OR (tumor) OR (tumours) OR (tumour) OR (metastasis) OR (metastases)))) AND (meta-analysis).

References

1. Treglia, G.; Sadeghi, R.; Del Sole, A.; Giovanella, L. Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: An evidence-based review. Clin. Transl. Oncol. 2014, 16, 770–775. [CrossRef] [PubMed]
2. Muoio, B.; Giovanella, L.; Treglia, G. Recent Developments of 18F-FET PET in Neuro-oncology. *Curr. Med. Chem.* 2018, 25, 3061–3073. [CrossRef] [PubMed]

3. Treglia, G. Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. *Contrast Media Mol. Imaging* 2019, 14. [CrossRef] [PubMed]

4. Mattoli, M.V.; Treglia, G.; Trevisi, G.; Muoio, B.; Cason, E. Usefulness of 11C-Methionine Positron Emission Tomography in Differential Diagnosis between Recurrent Tumours and Radiation Necrosis in Patients with Glioma: An Overview. *Open Neurosurg. J.* 2012, 5, 8–11. [CrossRef]

5. Bell, C.; Dowson, N.; Puttick, S.; Gal, Y.; Thomas, P.; Fay, M.; Smith, J.; Rose, S. Increasing feasibility and utility of (18) F-FDOPA PET for the management of glioma. *Nucl. Med. Biol.* 2015, 42, 788–795. [CrossRef]

6. Bertagna, F.; Biasiotti, G.; Giubbini, R. The role of F-18-fluorothymidine PET in oncology. *Clin. Transl. Imaging* 2013, 1, 77–97. [CrossRef]

7. Treglia, G.; Giovannini, E.; Di Franco, D.; Calcagni, M.L.; Rufini, V.; Picchio, M.; Giordano, A. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: A systematic review. *Ann. Nucl. Med.* 2012, 26, 451–461. [CrossRef]

8. Xiao, J.; Jin, Y.; Nie, J.; Chen, F.; Ma, X. Diagnostic and grading accuracy of (18) F-FDOPA PET and PET/CT in patients with gliomas: A systematic review and meta-analysis. *BMC Cancer* 2019, 19. [CrossRef] [PubMed]

9. Kim, S.J.; Ryu Shim, S. Diagnostic value of radiolabeled amino acid PET for detection of pseudoprogression of brain tumor after treatment: A meta-analysis. *Nucl. Med. Commun.* 2019, 40, 965–972. [CrossRef] [PubMed]

10. Zhang, Q.; Gao, X.; Wei, G.; Qiu, C.; Qu, H.; Zhou, X. Prognostic Value of MTV, SUVmax and the T/N Ratio of PET/CT in Patients with Glioma: A Systematic Review and Meta-Analysis. *J. Cancer* 2019, 10, 1707–1716. [CrossRef] [PubMed]

11. Katsanos, A.H.; Alexiou, G.A.; Fotopoulos, A.D.; Jabbour, P.; Kyritsis, A.P.; Sioka, C. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis. *Clin. Nucl. Med.* 2019. [CrossRef] [PubMed]

12. Furuse, M.; Nonoguchi, N.; Yamada, K.; Shiga, T.; Combes, J.D.; Ikeda, N.; Kawabata, S.; Kuroiwa, T.; Miyatake, S.I. Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: A systematic review. *Radiat. Oncol.* 2019, 14. [CrossRef] [PubMed]

13. Suh, C.H.; Kim, H.S.; Jung, S.C.; Choi, C.G.; Kim, S.J. Comparison of MRI and PET as Potential Surrogate Endpoints for Treatment Response After Stereotactic Radiosurgery in Patients with Brain Metastasis. *AJR Am. J. Roentgenol.* 2018, 211, 1332–1341. [CrossRef] [PubMed]

14. Gao, L.; Xu, W.; Li, T.; Zheng, J.; Chen, G. Accuracy of 11C-choline positron emission tomography in differentiating glioma recurrence from radiation necrosis: A systematic review and meta-analysis. *Medicine* 2018, 97. [CrossRef]

15. Kim, Y.I.; Kim, Y.; Lee, J.Y.; Jang, S.J. Prognostic Value of the Metabolic and Volumetric Parameters of (11) C-Methionine Positron-Emission Tomography for Gliomas: A Systematic Review and Meta-Analysis. *AJNR Am. J. Neuroradiol.* 2018, 39, 1629–1634. [CrossRef]

16. Yu, J.; Zheng, J.; Xu, W.; Weng, J.; Gao, L.; Tao, L.; Liang, F.; Zhang, J. Accuracy of (18) F-FDOPA Positron Emission Tomography and (18) F-FET Positron Emission Tomography for Differentiating Radiation Necrosis from Brain Tumor Recurrence. *World Neurosurg.* 2018, 114, 1211–1224. [CrossRef] [PubMed]

17. Li, H.; Deng, L.; Bai, H.X.; Sun, J.; Cao, Y.; Tao, Y.; States, L.J.; Farwell, M.D.; Zhang, P.; Xiao, B.; et al. Diagnostic Accuracy of Amino Acid and FDG-PET in Differentiating Brain Metastasis Recurrence from Radionecrosis after Radiotherapy: A Systematic Review and Meta-Analysis. *AJNR Am. J. Neuroradiol.* 2018, 39, 280–288. [CrossRef]

18. Xu, W.; Gao, L.; Shao, A.; Zheng, J.; Zhang, J. The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. *Oncotarget* 2017, 8, 91030–91039. [CrossRef]

19. Falk Delgado, A.; Falk Delgado, A. Discrimination between primary low-grade and high-grade glioma with (11) C-methionine PET: A bivariate diagnostic test accuracy meta-analysis. *Br. J. Radiol.* 2018, 91. [CrossRef]

20. Yang, Y.; He, M.Z.; Li, T.; Yang, X. MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: A systematic review and meta-analysis. *Neurosurg. Rev.* 2019, 42, 185–195. [CrossRef]

21. Verburg, N.; Hoefnagels, F.W.A.; Barkhof, F.; Boelhaar, R.; Goldman, S.; Guo, J.; Heimans, J.J.; Hoekestra, O.S.; Jain, R.; Kinoshita, M.; et al. Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. *AJNR Am. J. Neuroradiol.* 2017, 38, 1884–1891. [CrossRef] [PubMed]
22. Li, Y.; Tong, J.; Leng, H.; Jiang, J.; Pan, M.; Chen, Z. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis. *Oncotarget* 2017, 8, 41518–41528. [CrossRef] [PubMed]

23. Yang, M.; Sun, J.; Bai, H.X.; Tao, Y.; Tang, X.; States, L.J.; Zhang, Z.; Zhou, J.; Farwell, M.D.; Zhang, P.; et al. Diagnostic accuracy of SPECT, PET, and MRS for primary central nervous system lymphoma in HIV patients: A systematic review and meta-analysis. *Medicine (Baltimore)* 2017, 96. [CrossRef] [PubMed]

24. Li, Y.; Jin, G.; Su, D. Comparison of Gadolinium-enhanced MRI and 18FDG PET/CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies. *Oncotarget* 2017, 8, 35743–35749. [CrossRef] [PubMed]

25. Dunet, V.; Pomoni, A.; Hottinger, A.; Nicod-Lalonde, M.; Prior, J.O. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: Systematic review and meta-analysis. *Neuro Oncol.* 2016, 18, 426–434. [CrossRef] [PubMed]

26. Li, Z.; Yu, Y.; Zhang, H.; Xu, G.; Chen, L. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence. *Nucl. Med. Commun.* 2015, 36, 695–701. [CrossRef] [PubMed]

27. Wang, X.; Hu, X.; Xie, P.; Li, W.; Li, X.; Ma, L. Comparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: A diagnostic meta-analysis. *Asia Pac. J. Clin. Oncol.* 2015, 11, 97–105. [CrossRef] [PubMed]

28. Zhao, C.; Zhang, Y.; Wang, J. A meta-analysis on the diagnostic performance of (18) F-FDG and (11) C-methionine PET for differentiating brain tumors. *AJNR Am. J. Neuroradiol.* 2014, 35, 1058–1065. [CrossRef] [PubMed]

29. Deng, S.M.; Zhang, B.; Wu, Y.W.; Zhang, W.; Chen, Y.Y. Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: A meta-analysis. *Nucl. Med. Commun.* 2013, 34, 758–766. [CrossRef]

30. Nihashi, T.; Dahabreh, I.J.; Terasawa, T. Diagnostic accuracy of PET for recurrent glioma diagnosis: A meta-analysis. *AJNR Am. J. Neuroradiol.* 2013, 34, 944–950. [CrossRef] [PubMed]

31. Dunet, V.; Rossier, C.; Buck, A.; Stupp, R.; Prior, J.O. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: A systematic review and Metaanalysis. *J. Nucl. Med.* 2012, 53, 207–214. [CrossRef] [PubMed]

32. Law, I.; Albert, N.L.; Arbizu, J.; Boellaard, R.; Drzezga, A.; Galldiks, N.; Langen, K.J.; Lopci, E.; Lowe, V.; et al. Joint EANM/EANO/RANO practice guidelines/SNMNI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F] FDG: Version 1.0. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 540–557. [CrossRef] [PubMed]

33. Sadeghi, R.; Treglia, G. Systematic reviews and meta-analyses of diagnostic studies: A practical guideline. *Clin. Transl. Imaging* 2017, 5, 83–87. [CrossRef]

34. Treglia, G.; Sadeghi, R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: The state of the art. *Clin. Transl. Imaging* 2013, 1, 73–75. [CrossRef]

35. Galldiks, N.; Albert, N.L.; Sommerauer, M.; Grosu, A.L.; Ganswindt, U.; Law, I.; Preusser, M.; Le Rhun, E.; Vogelbaum, M.A.; Zadeh, G.; et al. PET imaging in patients with meningioma-report of the RANO/PET Group. *Neuro Oncol.* 2017, 19, 1576–1587. [CrossRef]

36. Sasikumar, A.; Kashyap, R.; Joy, A.; Charan Patro, K.; Bhattacharya, P.; Reddy Pilaka, V.K.; Oommen, K.E.; Pillai, M.R.A. Utility of 68Ga-PSMA-11 PET/CT in Imaging of Glioma-A Pilot Study. *Clin. Nucl. Med.* 2018, 43, 304–309. [CrossRef]

37. Michaud, L.; Beattie, B.J.; Akhurst, T.; Dunphy, M.; Zanzonico, P.; Finn, R.; Mauguen, A.; Schöder, H.; Weber, W.A.; Lassman, A.B.; et al. (18)F-Fluciclovine ((18) F-FACBC) PET imaging of recurrent brain tumors. *Eur. J. Nucl. Med. Mol. Imaging* 2019. [CrossRef]

38. Kamson, D.O.; Juhász, C.; Buth, A.; Kupsky, W.J.; Barger, G.R.; Chakraborty, P.K.; Muzik, O.; Mittal, S. Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates. *J. Neurooncol.* 2013, 112, 121–132. [CrossRef]

39. Heinzel, A.; Stock, S.; Langen, K.J.; Müller, D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. *Eur. J. Nucl. Med. Mol. Imaging* 2012, 39, 1089–1096. [CrossRef]

40. Heinzel, A.; Stock, S.; Langen, K.J.; Müller, D. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas. *J. Nucl. Med.* 2012, 53, 552–558. [CrossRef]
41. Heinzel, A.; Müller, D.; Langen, K.J.; Blaum, M.; Verburg, F.A.; Mottaghy, F.M.; Galldiks, N. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: A cost-effectiveness analysis. *J. Nucl. Med.* 2013, 54, 1217–1222. [CrossRef] [PubMed]
42. Heinzel, A.; Müller, D.; Yekta-Michael, S.S.; Ceccon, G.; Langen, K.J.; Mottaghy, F.M.; Wiesmann, M.; Kocher, M.; Hattingen, E.; Galldiks, N. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: An effectiveness and cost-effectiveness analysis. *Neuro Oncol.* 2017, 19, 1271–1278. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).